Norepinephrine shows no clear survival or neurologic benefit over epinephrine in shockable cardiac arrest according to recent human data and meta-analysis.
Does norepinephrine improve survival or neurologic outcomes in shockable cardiac arrest compared to epinephrine?
This commentary cautions that current evidence, heavily reliant on historical and heterogeneous animal studies, does not support a definitive survival or neurologic benefit of norepinephrine over epinephrine in shockable cardiac arrest.
Absolute Event Rate: 0% vs 0%
Norepinephrine in shockable cardiac arrest is a controversial topic. The review from Bouman et al. relies heavily on historical animal studies with limited human data, thus, their conclusion may not be clinically applicable. Current available data demonstrates significant heterogeneity, such as norepinephrine dosing and administration routes. Furthermore, a recent meta-analysis suggests no clear survival or neurologic benefit of norepinephrine over epinephrine. The assertions about neurologic outcomes, which were based on animal hemodynamics, were not supported by sufficient human evidence in the recent meta-analysis. Overall, the authors' conclusions may be too much of an overreach, due to given the variability and limitations of the included studies, warranting cautious interpretation.
Camp et al. (Wed,) reported a other. Norepinephrine shows no clear survival or neurologic benefit over epinephrine in shockable cardiac arrest according to recent human data and meta-analysis.